Patents by Inventor Xianfu Wu
Xianfu Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115753Abstract: An aroma diffuser comprises a compression plug connected to an air pump, an oil tube, an atomizing chamber, a spray outlet base, and a rotary spray outlet cover. The atomizing chamber comprises a chamber, a spray outlet sleeve, and a spray outlet, a distance between the air outlet and a chamber wall of the atomizing chamber is 11-13 times an aperture diameter of the air outlet, the spray outlet of the atomizing chamber extends downward to form a spray outlet channel, the spray outlet sleeve is sleeved outside of the spray outlet channel, atomized essential oil enters into the gaps between the spray outlet sleeve and the spray outlet channel from the groove notch and is then sprayed out, a bottom of the spray outlet sleeve is obliquely disposed and comprises a first reflux hole, and the rotary spray outlet cover is rotatably connected to the spray outlet base.Type: ApplicationFiled: December 12, 2022Publication date: April 11, 2024Inventors: Chaoqiang ZHAO, Xianfu LIN, Rongwei WU
-
Patent number: 10400031Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.Type: GrantFiled: October 5, 2017Date of Patent: September 3, 2019Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Todd G. Smith, Xianfu Wu
-
Publication number: 20180134767Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naive antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.Type: ApplicationFiled: October 5, 2017Publication date: May 17, 2018Applicant: The Government of the U.S.A. as rep. by the Secretary of the Dept.of Health and Human ServicesInventors: Todd G. Smith, Xianfu Wu
-
Patent number: 9809643Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.Type: GrantFiled: July 30, 2015Date of Patent: November 7, 2017Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Todd G. Smith, Xianfu Wu
-
Publication number: 20160114026Abstract: Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.Type: ApplicationFiled: December 22, 2015Publication date: April 28, 2016Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Xianfu Wu, Charles E. Rupprecht, Ivan V. Kuzmin
-
Patent number: 9248179Abstract: Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.Type: GrantFiled: June 23, 2011Date of Patent: February 2, 2016Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Xianfu Wu, Charles E. Rupprecht, Ivan V. Kuzmin
-
Publication number: 20160024185Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.Type: ApplicationFiled: July 30, 2015Publication date: January 28, 2016Applicant: The Government of the United States of America as represented by the Secretary of the Department ofInventors: Todd G. Smith, Xianfu Wu
-
Patent number: 9115187Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.Type: GrantFiled: October 18, 2011Date of Patent: August 25, 2015Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Todd G. Smith, Xianfu Wu
-
Patent number: 8865461Abstract: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.Type: GrantFiled: November 30, 2010Date of Patent: October 21, 2014Assignee: The United States of America as represtented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Charles E. Rupprecht, Xianfu Wu
-
Patent number: 8524247Abstract: Described herein are recombinant rabies viruses comprising a heterologous nucleic acid sequence encoding an immunocontraceptive protein, such as gonadotropin-releasing hormone (GnRH) or zona pellucida 3 (ZP3). The recombinant rabies viruses disclosed herein are recovered by reverse genetics, replicate efficiently, elicit rabies virus neutralizing antibodies and immunocontraceptive peptide-specific antibodies in vaccinated animals, and protect vaccinated animals against wild-type rabies virus challenge. Further provided is a method of immunizing a non-human animal against rabies virus infection and simultaneously inhibiting fertility of the animal, comprising administering an immunogenic composition comprising one or more of the recombinant rabies viruses described herein.Type: GrantFiled: August 20, 2009Date of Patent: September 3, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Xianfu Wu, Charles Rupprecht
-
Publication number: 20130224207Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.Type: ApplicationFiled: October 18, 2011Publication date: August 29, 2013Applicants: Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Todd G. Smith, Xianfu Wu
-
Publication number: 20130095137Abstract: Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.Type: ApplicationFiled: June 23, 2011Publication date: April 18, 2013Applicant: The Government of the United States of America as Represented by the Secretary of the Department ofInventors: Xianfu Wu, Charles E. Rupprecht, Ivan V. Kuzmin
-
Publication number: 20110165189Abstract: Described herein are recombinant rabies viruses comprising a heterologous nucleic acid sequence encoding an immunocontraceptive protein, such as gonadotropin-releasing hormone (GnRH) or zona pellucida 3 (ZP3). The recombinant rabies viruses disclosed herein are recovered by reverse genetics, replicate efficiently, elicit rabies virus neutralizing antibodies and immunocontraceptive peptide-specific antibodies in vaccinated animals, and protect vaccinated animals against wild-type rabies virus challenge. Further provided is a method of immunizing a non-human animal against rabies virus infection and simultaneously inhibiting fertility of the animal, comprising administering an immunogenic composition comprising one or more of the recombinant rabies viruses described herein.Type: ApplicationFiled: August 20, 2009Publication date: July 7, 2011Inventors: Xianfu Wu, Charles Rupprecht
-
Publication number: 20110070264Abstract: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.Type: ApplicationFiled: November 30, 2010Publication date: March 24, 2011Inventors: Charles E. Rupprecht, Xianfu Wu
-
Patent number: 7863041Abstract: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.Type: GrantFiled: October 13, 2006Date of Patent: January 4, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Charles E. Rupprecht, Xianfu Wu
-
Publication number: 20080274130Abstract: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.Type: ApplicationFiled: October 13, 2006Publication date: November 6, 2008Applicant: The Govt. of the U.S.A. as Represented by the Secretary of the Dept.of Health and Human ServicesInventors: Charles E. Rupprecht, Xianfu Wu